Article

Avastin for Refractory Glioblastoma and Oxaliplatin for Colon Cancer

As presented at ASCO, second-line bevacizumab (Avastin) as monotherapy has been associated with a 28% response rate and an overall survival edge for refractory glioblastoma. Also presented at the ASCO meeting, adding oxaliplatin (Eloxatin) to a standard chemotherapy regimen for stage II or III colon cancer may provide a small five-year survival advantage.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Christine Frissora, MD | Credit: Weill Cornell
Hope on the Horizon: 2 Food Allergy Breakthroughs in 2024
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
Study Highlights Comorbidities Before, After Bullous Pemphigoid Diagnosis
December 21st 2024

Study Highlights Comorbidities Before, After Bullous Pemphigoid Diagnosis

Tim Smith
Video: Exploring Bempedoic Acid: Clinical Indications, Efficacy, and Future Directions in Cardiovascular Risk Management
December 17th 2024

Video: Exploring Bempedoic Acid: Clinical Indications, Efficacy, and Future Directions in Cardiovascular Risk Management

Pam R. Taub, MD, FACC, FASPC Marc P. Bonaca, MD, MPH
Liver | Credit: Adobe Stock
December 21st 2024

Machine Learning Model Accurately Predicts Long-Term HCC Risk in Patients with HBV

Abigail Brooks, MA
Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor
December 16th 2024

Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
CASPAR Criteria May Identify More Patients With Juvenile PsA Than ILAR Criteria
December 21st 2024

CASPAR Criteria May Identify More Patients With Juvenile PsA Than ILAR Criteria

Victoria Johnson
FDA Approves Tirzepatide for Obstructive Sleep Apnea in Obesity | Image Credit: US Food and Drug Administration
December 20th 2024

FDA Approves Tirzepatide for Obstructive Sleep Apnea in Obesity

Connor Iapoce
© 2024 MJH Life Sciences

All rights reserved.